VIVEK SUBBIAH to Diarrhea
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Diarrhea.
Connection Strength
0.306
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.182
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
Score: 0.043
-
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
Score: 0.041
-
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2022 02 03; 27(1):13-21.
Score: 0.040